Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia

Blood

Volumn 127, Issue 8, 2016, Pages 977-988

  Sheikh, Virginia ^a   Porter, Brian O ^a   DerSimonian, Rebecca ^a   Kovacs, Stephen B ^b   Thompson, William L ^a   Perez Diez, Ainhoa ^a   Freeman, Alexandra F ^a   Roby, Gregg ^a   Mican, Joann ^a   Pau, Alice ^a   Rupert, Adam ^b   Adelsberger, Joseph ^b   Higgins, Jeanette ^b   Bourgeois, Jeffrey S ^a   Jensen, Stig M R ^a   Morcock, David R ^b   Burbelo, Peter D ^c   Osnos, Leah ^a   Maric, Irina ^d   Natarajan, Ven ^b   Croughs, Therese ^e   Yao, Michael D ^a   Estes, Jacob D ^b   Sereti, Irini ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e Cytheris SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; DRUG ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; RECOMBINANT INTERLEUKIN 7; IMMUNOLOGIC FACTOR; INTERLEUKIN 7; RECOMBINANT PROTEIN;

ADULT; AGED; ALLERGIC REACTION; ANTIBODY PRODUCTION; ARTICLE; BONE MARROW; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CYTOKINE PRODUCTION; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FLUSHING; FOLLOW UP; HUMAN; HUMAN TISSUE; IDIOPATHIC CD4 LYMPHOCYTOPENIA; IDIOPATHIC DISEASE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INJECTION SITE REACTION; INTESTINE MUCOSA; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; MALAISE; MALE; MIDDLE AGED; MYALGIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIDE EFFECT; TISSUE DISTRIBUTION; TREATMENT OUTCOME; YOUNG ADULT; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; IMMUNOPHENOTYPING; T-LYMPHOCYTOPENIA, IDIOPATHIC CD4-POSITIVE;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOPHENOTYPING; INTERLEUKIN-7; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; T-LYMPHOCYTOPENIA, IDIOPATHIC CD4-POSITIVE; YOUNG ADULT;

EID: 84960414465     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-05-645077     Document Type: Article

References (51)

1. Smith DK, Neal JJ, Holmberg SD. Unexplained opportunistic infections and CD41 T-lymphocytopenia without HIV infection. An investigation of cases in the United States. The Centers for Disease Control Idiopathic CD41 T-lymphocytopenia Task Force. N Engl J Med. 1993;328(6):373-379.
2. Régent A, Autran B, Carcelain G, et al; French Idiopathic CD4 T Lymphocytopenia Study Group. Idiopathic CD4 lymphocytopenia: clinical and immunologic characteristics and follow-up of 40 patients. Medicine (Baltimore). 2014;93(2):61-72.
3. Zonios DI, Falloon J, Bennett JE, et al. Idiopathic CD41 lymphocytopenia: natural history and prognostic factors. Blood. 2008;112(2):287-294.
4. Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood. 2002;99(11):3892-3904.
5. Mazzucchelli R, Durum SK. Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol. 2007;7(2):144-154.
6. Ferrari G, Berend C, Ottinger J, et al. Replicationdefective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy. Blood. 1997;90(6):2406-2416.
7. Melchionda F, Fry TJ, Milliron MJ, McKirdy MA, Tagaya Y, Mackall CL. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD81 memory cell pool. J Clin Invest. 2005;115(5):1177-1187.
8. Sereti I, Dunham RM, Spritzler J, et al; ACTG 5214 Study Team. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood. 2009;113(25):6304-6314.
9. Lévy Y, Sereti I, Tambussi G, et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis. 2012;55(2): 291-300.
10. Levy Y, Lacabaratz C, Weiss L, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest. 2009;119(4): 997-1007.
11. Sportès C, Babb RR, Krumlauf MC, et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res. 2010;16(2): 727-735.
12. Perales MA, Goldberg JD, Yuan J, et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood. 2012;120(24): 4882-4891.
13. Puronen CE, Thompson WL, Imamichi H, et al. Decreased interleukin 7 responsiveness of T lymphocytes in patients with idiopathic CD4 lymphopenia. J Infect Dis. 2012;205(9): 1382-1390.
14. Fry TJ, Christensen BL, Komschlies KL, Gress RE, Mackall CL. Interleukin-7 restores immunity in athymic T-cell-depleted hosts. Blood. 2001;97(6): 1525-1533.
15. Fry TJ, Mackall CL. Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol. 2001;22(10):564-571.
16. Fry TJ, Connick E, Falloon J, et al. A potential role for interleukin-7 in T-cell homeostasis. Blood. 2001;97(10):2983-2990.
17. Sportès C, Hakim FT, Memon SA, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med. 2008;205(7):1701-1714.
18. Kovacs SB, Sheikh V, Thompson WL, et al. T-cell depletion in the colonic mucosa of patients with idiopathic CD41 lymphopenia. J Infect Dis. 2015; 212(10):1579-1587.
19. Sereti I, Estes JD, Thompson WL, et al. Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration. PLoS Pathog. 2014;10(1):e1003890.
20. Ishida T, Hashimoto T, Arita M, Ito I, Osawa M. Pulmonary Mycobacterium avium disease in a young patient with idiopathic CD41 T lymphocytopenia. Intern Med. 1998;37(7): 622-624.
21. Jha S, Ghosh P, Agarwal V. Cryptococcal meningitis unmasking idiopathic CD4 lymphocytopenia. Neurol India. 2007;55(3): 312-314.
22. Kawabata T, Matsuyama W, Higashimoto I, et al. Pleural cryptococcosis with idiopathic CD4 positive T-lymphocytopenia. Intern Med. 2008; 47(19):1765.
23. Kofteridis DP, Saridaki Z, Kazakou I, et al. Idiopathic CD41 T lymphocytopenia disclosed by recurrent cryptococcal meningitis. First case report from Greece. Int J Infect Dis. 2005;9(6): 347-348.
24. López-Medrano F, Aguado JM, Ruiz-Contreras J, et al. Idiopathic CD41 T lymphocytopenia disclosed after the diagnosis of Visceral leishmaniasis. Clin Infect Dis. 2007;44(11): 1522-1523.
25. McLane NJ, Weems JJ Jr, Antworth MV. Cytomegalovirus retinitis in a patient with idiopathic CD41 T lymphocytopenia. Clin Infect Dis. 1994;18(6):1012-1013.
26. Plonquet A, Bassez G, Authier FJ, Dray JM, Farcet JP, Gherardi RK. Toxoplasmic myositis as a presenting manifestation of idiopathic CD4 lymphocytopenia. Muscle Nerve. 2003;27(6): 761-765.
27. Prigione I, Castagnola E, Imberti L, et al. Multiple relapses of visceral leishmaniasis in an adolescent with idiopathic CD41 lymphocytopenia associated with novel immunophenotypic and molecular features. Pediatr Infect Dis J. 2009;28(2):161-163.
28. Thoden J, Venhoff N, Daskalakis M, et al. Disseminated tuberculosis in a patient with idiopathic CD41 lymphocytopenia. Rheumatology (Oxford). 2009;48(10):1329-1330.
29. Zonios DI, Falloon J, Huang CY, Chaitt D, Bennett JE. Cryptococcosis and idiopathic CD4 lymphocytopenia. Medicine (Baltimore). 2007; 86(2):78-92.
30. Anzalone G, Cei M, Vizzaccaro A, Tramma B, Bisetti A. M. Kansasii pulmonary disease in idiopathic CD41 T-lymphocytopenia. Eur Respir J. 1996;9(8):1754-1756.
31. Burg S, Weber W, Kücherer C. [Idiopathic CD4 lymphocytopenia with lethal Salmonella typhimurium sepsis] [in German]. Dtsch Med Wochenschr. 1994;119(27):956-958.
32. Delgado-Alvarado M, Sedano MJ, González-Quintanilla V, de Lucas EM, Polo JM, Berciano J. Progressive multifocal leukoencephalopathy and idiopathic CD4 lymphocytopenia. J Neurol Sci. 2013;327(1-2):75-79.
33. Hochauf K, Bandt D, Pöhlmann C, Monecke S, Toma M, Trautmann S. Fatal varicella zoster virus infection as first manifestation of idiopathic CD41 T-cell lymphocytopenia. Eur J Clin Microbiol Infect Dis. 2005;24(10):706-708.
34. Augusto E, Raguenaud ME, Kim C, Mony M, Isaakidis P. Idiopathic CD41 T-lymphocytopenia with cryptococcal meningitis: first case report from Cambodia. Trop Doct. 2009;39(3):176-177.
35. Böhm M, Luger TA, Bonsmann G. Disseminated giant molluscum contagiosum in a patient with idiopathic CD41 lymphocytopenia. Successful eradication with systemic interferon. Dermatology. 2008;217(3):196-198.
36. Eftekhari K, Say EA, Shields CL, Gausas RE, Shields JA. Orbital lymphoma in the setting of idiopathic CD41 lymphocytopenia (HIV-negative AIDS). Ophthal Plast Reconstr Surg. 2011;27(5): e134-e136.
37. Kojima M, Sakurai S, Morita Y, Nakamura N, Sugihara S, Shimano S. EBV(1) B-cell lymphoproliferative disorder associated with subsequent development of Burkitt lymphoma in a patient with idiopathic CD4(1) Tlymphocytopenia. J Clin Exp Hematop. 2008; 48(2):55-59.
38. Park K, Monk BJ, Wilczynski S, Ito JI Jr, Vasilev SA. Idiopathic CD41 T-lymphocytopenia and recurrent vulvar intraepithelial neoplasia. Obstet Gynecol. 1994;84(4 Pt 2):712-714.
39. Purnell D, Ilchyshyn A, Jenkins D, Salim A, Seth R, Snead D. Isolated human papillomavirus 18-positive extragenital bowenoid papulosis and idiopathic CD41 lymphocytopenia. Br J Dermatol. 2001;144(3):619-621.
40. Rijnders RJ, van den Ende IE, Huikeshoven FJ. Suspected idiopathic CD41 T-lymphocytopenia in a young patient with vulvar carcinoma stage IV. Gynecol Oncol. 1996;61(3):423-426.
41. Ben Rejeb A, Ebdelli N, Bouali MR, et al. [Primary digestive tract Kaposi sarcoma with idiopathic CD41 lymphocytopenia, HIV negative, HHV8 positive] [in French]. Gastroenterol Clin Biol. 2001;25(6-7):707-710.
42. Fierro MT, Savoia P, Quaglino P, Novero D, Bernengo MG. Disseminated Kaposi's sarcoma associated with idiopathic CD41 lymphocytopenia and low dose steroid therapy. Clin Exp Dermatol. 2005;30(4):395-397.
43. Uckun FM, Tuel-Ahlgren L, Obuz V, et al. Interleukin 7 receptor engagement stimulates tyrosine phosphorylation, inositol phospholipid turnover, proliferation, and selective differentiation to the CD4 lineage by human fetal thymocytes. Proc Natl Acad Sci USA. 1991;88(14):6323-6327.
44. Wallace DL, Bérard M, Soares MV, et al. Prolonged exposure of naïve CD81 T cells to interleukin-7 or interleukin-15 stimulates proliferation without differentiation or loss of telomere length. Immunology. 2006;119(2):243-253.
45. Tsukuda M, Mochimatsu I, Sakumoto M, Mikami Y, Yuyama S, Yanoma S. The synergistic effects of interleukin 2 and interleukin 7 on the proliferation and autologous tumor cell lysis of tumor-associated lymphocytes. Biotherapy. 1993; 6(3):167-174.
46. Normanton M, Alvarenga H, Hamerschlak N, et al. Interleukin 7 plays a role in T lymphocyte apoptosis inhibition driven by mesenchymal stem cell without favoring proliferation and cytokines secretion. PLoS One. 2014;9(9): e106673.
47. Bignon A, Régent A, Klipfel L, et al. DUSP4-mediated accelerated T-cell senescence in idiopathic CD4 lymphopenia. Blood. 2015; 125(16):2507-2518.
48. Finkelman FD, Madden KB, Morris SC, et al. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol. 1993;151(3): 1235-1244.
49. Alstadhaug KB, Croughs T, Henriksen S, et al. Treatment of progressive multifocal leukoencephalopathy with interleukin 7. JAMA Neurol. 2014;71(8):1030-1035.
50. Gasnault J, de Goër de Herve MG, Michot JM, et al. Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy. Open Forum Infect Dis. 2014;1(2):ofu074.
51. Sospedra M, Schippling S, Yousef S, et al. Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1. Clin Infect Dis. 2014;59(11):1588-1592.